Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: PR Newswire
TARRYTOWN, N.Y., April 6, 2020 /PRNewswire/ --Company to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 5, 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company has finalized the planned Praluent® (alirocumab) restructuring with Sanofi. Regeneron also announced important changes to its accounting presentation effective January 1, 2020.The new Praluent agreements, effective April 1, 2020, simplify the antibody collaboration between the companies, increasing efficiency and streamlining operations. In the U.S., Regeneron will have sole responsibility for Praluent and record net product sales. Sanofi will have sole responsibility outside the U.S. and pay Regeneron a royalty on Praluent net product sales. Changes in Accounting PresentationEffective January 1, 2020, Regeneron has implemented changes in the presentation of its consolidated financial statements related to certain reimbursements and other payments for products devel
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]Yahoo! Finance
- Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]Yahoo! Finance
- BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]Yahoo! Finance
- AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]Yahoo! Finance
- Regeneron CEO: AI is as good as the data it can train on [CNBC]CNBC
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 4
- 1/7/26 - Form 144
- REGN's page on the SEC website